SEC Awards Over $50 Million to Joint Whistleblowers

Washington, D.C.--(Newsfile Corp. - April 15, 2021) - The Securities and Exchange Commission today announced an award of over $50 million to joint whistleblowers whose information alerted SEC staff to violations that involved highly complex transactions and would have been difficult to detect without their information.

The joint whistleblowers provided exemplary assistance to the SEC staff during the investigation, including meeting with staff numerous times and providing voluminous detailed documents.The information provided by these individuals resulted in the return of tens of millions of dollars to harmed investors.

Todays award is the second largest in the history of the program, reflecting the tremendous contribution of these joint whistleblowers to our ability to recover funds for harmed investors, said Jane Norberg, Chief of the SECs Office of the Whistleblower. The SEC has now awarded over a quarter of a billion dollars to whistleblowers in the first seven months of this fiscal year alone, demonstrating the tremendous value of whistleblowers to our enforcement program.

The SEC has now awarded approximately $812 million to 151 individuals since issuing its first award in 2012.All payments are made out of an investor protection fund established by Congress that is financed entirely through monetary sanctions paid to the SEC by securities law violators. No money has been taken or withheld from harmed investors to pay whistleblower awards. Whistleblowers may be eligible for an award when they voluntarily provide the SEC with original, timely, and credible information that leads to a successful enforcement action.Whistleblower awards can range from 10 percent to 30 percent of the money collected when the monetary sanctions exceed $1 million.

For more information about the whistleblower program and how to submit a tip, visit www.sec.gov/whistleblower.

You May Also Be Interested In

• Vertical Data names interim CFO to lead stock exchange uplisting
• HawkEye 360 wins NRO contract for commercial RF data services
• Propanc Biopharma begins prep for Phase 1b cancer therapy trial in Australia